Oncogenes

Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046

Retrieved on: 
Friday, May 29, 2020
Oncogenes, Proto-oncogene tyrosine-protein kinase Src, Protein kinase inhibitor

Specifically, in preclinical studies, TPX-0046 inhibited RET solvent front mutations that have been observed in biopsies from patients with progression on a prior RET inhibitor.

Key Points: 
  • Specifically, in preclinical studies, TPX-0046 inhibited RET solvent front mutations that have been observed in biopsies from patients with progression on a prior RET inhibitor.
  • TPX-0046 is a multi-targeted RET and SRC kinase inhibitor with a novel three-dimensional macrocyclic structure that is smaller and structurally distinguished from other approved or investigational RET inhibitors.
  • Dual inhibition of RET and SRC represents a novel therapeutic strategy to target abnormal RET signaling in cancers.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio

Retrieved on: 
Friday, May 15, 2020
Chemical compounds, Organic compounds, Heterocyclic compounds, Orphan drugs, Breakthrough therapy, Triazines, Piperazines, Oncogenes, Venetoclax, Bcl-2, Ivosidenib, IDH1

; Abstract #S157

Key Points: 
  • ; Abstract #S157
    Kinetics of Response in the Peripheral Blood Predicts Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Bloodwise TAP CLARITY trial.
  • ; Abstract #EP535
    Real-World Data (RWD) Cohort of Patients with Acute Myeloid Leukemia (AML) in the United States from an Electronic Health Record (EHR)Derived De-Identified Database.
  • ; Abstract #EP1739
    Phase 1b/2 Study of the IDH1-Mutant Inhibitor Ivosidenib with the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies.
  • In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.

Insights into the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market (2017 to 2030) - Featuring AstraZeneca, Pfizer & Takeda Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 14, 2020
Pharmaceutical, Health, Oncology, Lung cancer, Cancer, Clinical medicine, Medicine, Quinazolines, Epidermal growth factor receptor, Oncogenes, Astellas Pharma, Treatment of lung cancer, OSI Pharmaceuticals

Launch of emerging therapies, will significantly impact the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.

Key Points: 
  • Launch of emerging therapies, will significantly impact the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.
  • To understand the future market competition in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.
  • To understand the future market competition in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 14, 2020
Health, Oncology, Lung cancer, Cancer, Tyrosine kinase receptors, Clinical medicine, Branches of biology, Epidermal growth factor receptor, Oncogenes, Tyrosine kinase inhibitors, Treatment of lung cancer, CimaVax-EGF

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermal growth factor receptor-Non Small Cell Lung Cancer?

Key Points: 
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermal growth factor receptor-Non Small Cell Lung Cancer?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Epidermal growth factor receptor-Non Small Cell Lung Cancer?
  • Quantify patient populations in the global Epidermal growth factor receptor-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans
    The Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.
  • Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
    4.1.

Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Retrieved on: 
Thursday, May 14, 2020
Enzymes, Tyrosine kinase receptors, Tyrosine kinases, CD135, Bruton's tyrosine kinase, Tumors of the hematopoietic and lymphoid tissues, Oncology, Protein kinase inhibitor, C-Met, Oncogenes, Morpholines, ETV6

The accepted abstract is available online on the EHA conference website, ehaweb.org .

Key Points: 
  • The accepted abstract is available online on the EHA conference website, ehaweb.org .
  • CG-806 is an oral, first-in-class FLT3/BTK cluster selective kinase inhibitor and is in Phase 1 clinical studies for the treatment of hematologic malignancies.
  • Because CG-806 targets key kinases/pathways operative in malignancies derived from the bone marrow, it is in development for B-cell cancers and AML.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories

Retrieved on: 
Thursday, May 14, 2020
Branches of biology, Medicine, Clinical medicine, Oncogenes, Biotechnology, Biomarkers, Assay, Biochemistry, Titration, BRAF, Melanoma, Epidermal growth factor receptor

The BRAF molecular assay kit is designed for the BRAF mutation, which is among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma.

Key Points: 
  • The BRAF molecular assay kit is designed for the BRAF mutation, which is among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma.
  • Biocept previously launched its molecular assay kit for the detection of EGFR mutations and plans to release additional Target Selector molecular assay kits in the future.
  • Biocept's Target Selector assay technology is patent protected in the United States, seven countries in Europe and five international territories.
  • "Our patented Switch-Blocker technology provides the unique ability to block the normal DNA and only analyze the target area of interest.

Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Biology, Life sciences, Apoptosis, Bcl-2, Oncogenes, Programmed cell death, Antisense therapy, Chronic lymphocytic leukemia, Oncology

HOUSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2020American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-31, 2020.

Key Points: 
  • HOUSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2020American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-31, 2020.
  • Dr. Maro Ohanian, Department of Leukemia, University of Texas M.D.
  • The Companys second pipeline candidate is BP1002, which targets the Bcl-2 protein and is planned to be evaluated for the treatment of lymphoma and chronic lymphocytic leukemia.
  • In addition, an IND application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, is expected to be filed in 2020.

Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020

Retrieved on: 
Friday, May 8, 2020
Branches of biology, Apoptosis, Oncogenes, Programmed cell death, Bcl-2, Lymphoma

ET to report financial results for the first quarter ended March 31, 2020 and to provide a business overview.

Key Points: 
  • ET to report financial results for the first quarter ended March 31, 2020 and to provide a business overview.
  • A live audio webcast of the call will also be available on the Events section of the Companys website, www.biopathholdings.com .
  • An archived webcast will be available on the Bio-Path website approximately two hours after the event.
  • This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies.

Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020

Retrieved on: 
Thursday, May 7, 2020
Cell Cycle, Cyclin-dependent kinase 4, Oncogenes, Proteins, Protein kinase inhibitors, CDK inhibitor

ET on the same day to discuss these results and provide an update on its pipeline programs.

Key Points: 
  • ET on the same day to discuss these results and provide an update on its pipeline programs.
  • To facilitate an on-time conference call start, Onconova recommends that participants dial in 15 minutes before the 4:30 p.m.
  • Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and ARK5 inhibitor, ON 123300.
  • These statements relate to Onconova expectations regarding the INSPIRE Trial and Onconovas other development plans.

Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies

Retrieved on: 
Thursday, April 30, 2020
Branches of biology, Cell biology, Biology, Programmed cell death, Bcl-2, Oncogenes, Apoptosis, Selective estrogen receptor degrader, Cancer, p53 upregulated modulator of apoptosis, Germinal center B-cell like diffuse large B-cell lymphoma

BCL-2 is as an important mediator in restoring the normal apoptotic process in tumor cells, making this protein a vital target for the treatment of cancer.

Key Points: 
  • BCL-2 is as an important mediator in restoring the normal apoptotic process in tumor cells, making this protein a vital target for the treatment of cancer.
  • ZN-d5, a BCL-2 inhibitor, may offer patients with hematologic and epithelial malignancies a differentiated therapy option, both as a monotherapy and in combination with other agents including our oral selective estrogen receptor degrader (SERD), ZN-c5.
  • We believe a BCL-2 inhibitor will restore the normal apoptosis process, making it an important target for cancer treatments.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.